PCOS renamed to PMOS: what the global nomenclature shift means for Canadian patients and clinicians

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

A 2026 correspondence published in The Lancet argues that polycystic ovary syndrome (PCOS) should be renamed polycystic/metabolic ovary syndrome (PMOS), on the grounds that the existing name has caused decades of diagnostic confusion by implying the condition is primarily about ovarian cysts. For the roughly one in ten Canadian women and people with ovaries who live with this condition, the proposed change is more than semantic: it could reshape how family physicians screen for it, how endocrinologists and gynecologists code it, and whether provincial pharmacare programs eventually broaden coverage of metabolic treatments.

PCOS is the most common endocrine disorder affecting people with ovaries in Canada, characterized by hormonal imbalance, irregular or absent ovulation, and often elevated androgens (male-type hormones such as testosterone). Many patients also have insulin resistance and a higher lifetime risk of type 2 diabetes, cardiovascular disease, and endometrial cancer. The name "polycystic ovary syndrome" has long drawn criticism because many people diagnosed with PCOS do not have visible cysts on ultrasound, and many people who do have cysts do not have the syndrome. The Lancet authors contend that "PMOS" would signal to both patients and clinicians that metabolic dysfunction sits at the center of the diagnosis, not ovarian morphology.

What this means in Canada

Health Canada has not issued any statement on the proposed renaming, and the Society of Obstetricians and Gynaecologists of Canada (SOGC) has not yet released a position statement on PMOS terminology. The current Canadian clinical standard follows the 2023 international evidence-based guideline developed jointly by Monash University and a coalition of international societies, which retained the PCOS name while substantially broadening diagnostic criteria and emphasizing metabolic and psychological care. That guideline is referenced by Canadian clinicians but has not been formally adopted as a SOGC policy document.

In terms of drug coverage, the treatments most commonly used for PCOS in Canada are not changing regardless of what the condition is called. Metformin (sold in Canada as Glucophage and in generic form) is covered under most provincial formularies, including the Ontario Drug Benefit (ODB), Quebec's RAMQ, British Columbia's PharmaCare, and Alberta's AHCIP, when prescribed for metabolic indications. Combined oral contraceptives used to regulate cycles are similarly covered in most provinces for patients who qualify. Spironolactone, used off-label for androgen-related symptoms such as acne and excess hair growth, has variable provincial coverage. A name change to PMOS would not automatically alter any of these coverage categories; that would require Health Canada to update its drug indication language and provincial formulary committees to follow.

Canadian telehealth platforms that serve patients with hormonal conditions, including Cleo (a Canadian women's-health platform), Felix, and Science & Humans (scienceandhumans.com), currently use PCOS terminology in their intake and clinical documentation. None has publicly announced plans to update to PMOS pending regulatory or professional-society guidance.

Why this matters

The naming debate is not new, but the Lancet correspondence gives it fresh visibility at a moment when metabolic health is receiving more clinical attention globally. The core argument is that a name drives clinical behavior. When a physician hears "polycystic ovary syndrome," the mental model defaults to the ovary and to gynecology. When a patient is told she has a "syndrome" defined by cysts, she may not understand why her doctor is ordering a fasting glucose test or discussing cardiovascular risk. Renaming the condition to include "metabolic" would, the authors argue, prompt earlier referral to endocrinology, more consistent screening for insulin resistance, and better patient comprehension of long-term health risks.

There is also a diagnostic gap the name change is meant to address. A significant proportion of people with PCOS are diagnosed late, often after years of being told their irregular periods are stress-related or their acne is cosmetic. In Canada, patient advocacy groups and clinicians have documented this delay repeatedly. The Canadian Institutes of Health Research (CIHR) has funded research into PCOS burden, and a 2022 survey cited in CMAJ Open found that Canadian patients waited an average of two years from symptom onset to diagnosis. Proponents of the PMOS label argue that a more descriptive name could shorten that gap by prompting metabolic screening earlier in primary care.

What Canadian patients should know

If you have a PCOS diagnosis, nothing about your treatment changes today because of this Lancet correspondence. A published letter, even in a journal of The Lancet's standing, is not a regulatory or clinical-society decision. Your diagnosis remains valid, your prescriptions remain valid, and your provincial coverage is unaffected.

What is worth discussing with your physician or nurse practitioner is whether your care plan addresses the metabolic dimensions of your condition, regardless of what it is called. The 2023 international PCOS guideline recommends that all patients be assessed for insulin resistance, cardiovascular risk factors, and mental health, not just cycle irregularity or fertility concerns. If your care has focused narrowly on one symptom, asking for a broader metabolic workup is reasonable.

Provincial access to specialists varies. In Ontario, a referral to an endocrinologist or a reproductive endocrinologist is covered under OHIP but wait times can run six to eighteen months in many regions. In British Columbia and Alberta, similar specialist access is covered but geographically uneven. Quebec's RAMQ covers specialist visits, though French-language resources specific to PCOS/PMOS remain limited outside Montreal.

For patients in areas with limited specialist access, Canadian telehealth services can provide initial hormonal assessments and prescriptions for first-line treatments, though complex metabolic management typically requires in-person specialist care.

Limitations and open questions

The Lancet piece is a correspondence, not a clinical trial or a systematic review. It represents the perspectives of its authors, not a consensus of any regulatory or professional body. The SOGC has not issued a position statement on PMOS. Health Canada has not indicated whether it would update its disease classification language. The International Classification of Diseases (ICD-11), which Canadian hospitals use for coding, still lists the condition under PCOS terminology, and any change there would require a separate WHO process.

It is also not settled that renaming a condition changes clinical outcomes. Nomenclature reform in medicine has a mixed track record. Whether PMOS would actually reduce diagnostic delay or improve metabolic screening in Canadian primary care is an empirical question that has not been studied.

What the Lancet correspondence does is put the question formally on the table for professional societies, regulators, and patient advocates to respond to. Canadian patients and clinicians should watch for SOGC and Health Canada responses in the months ahead.

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.